Integra LifeSciences (NASDAQ:IART) Stock Price Target Lowered at Citizens Jmp

Key Points

• Citizens JMP lowered Integra LifeSciences’ price target from $25 to $22 but maintained a “market outperform” rating, implying roughly 84% upside from the stock’s $11.93 price.
• Analyst sentiment remains mixed: Integra has an average “hold” rating and a consensus price target of $17.25, with JPMorgan lowering its target to $14 and assigning an “underweight” rating.
• Integra exceeded quarterly earnings expectations with EPS of $0.59 versus a $0.56 consensus, though revenue of $411.18 million fell slightly short of estimates and the company reported a negative net margin.

Integra LifeSciences (NASDAQ:IART - Get Free Report) had its target price cut by equities researchers at Citizens Jmp from $25.00 to $22.00 in a report issued on Thursday, Benzinga reports. The brokerage presently has a "market outperform" rating on the life sciences company's stock. Citizens Jmp's target price points to a potential upside of 84.49% from the company's current price.

Other research analysts also recently issued research reports about the stock. Wall Street Zen downgraded shares of Integra LifeSciences from a "buy" rating to a "hold" rating in a research report on Saturday, October 3rd. BMO Capital Markets reissued a "market perform" rating on shares of Integra LifeSciences in a research report on Thursday. JPMorgan Chase & Co. reduced their price objective on shares of Integra LifeSciences from $17.00 to $14.00 and set an "underweight" rating for the company in a research note on Thursday. UBS Group started coverage on Integra LifeSciences in a report on Tuesday, July 28th. They issued a "neutral" rating and a $19.00 price objective for the company. Finally, Weiss Ratings cut Integra LifeSciences from a "sell (d-)" rating to a "sell (e+)" rating in a report on Friday, October 2nd. Three equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus price target of $17.25.

Integra LifeSciences Stock Up 0.7%

NASDAQ:IART traded up $0.09 during trading hours on Thursday, reaching $11.93. 284,433 shares of the stock were exchanged, compared to its average volume of 909,438. Integra LifeSciences has a twelve month low of $8.70 and a twelve month high of $20.49. The company has a debt-to-equity ratio of 1.75, a current ratio of 3.60 and a quick ratio of 2.11. The firm has a 50 day moving average of $15.56 and a 200 day moving average of $15.56. The stock has a market cap of $927.41 million, a PE ratio of -132.37, a PEG ratio of 0.71 and a beta of 1.21.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last issued its quarterly earnings results on Wednesday, October 21st. The life sciences company reported $0.59 earnings per share for the quarter, topping the consensus estimate of $0.56 by $0.03. Integra LifeSciences had a negative net margin of 0.44% and a positive return on equity of 18.30%. The company had revenue of $411.18 million during the quarter, compared to analysts' expectations of $413.16 million. During the same period last year, the business earned ($0.07) EPS. On average, equities analysts expect that Integra LifeSciences will post 2.39 earnings per share for the current year.

Institutional Trading of Integra LifeSciences

A number of large investors have recently added to or reduced their stakes in the company. Paradigm Capital Management Inc. NY increased its stake in shares of Integra LifeSciences by 50.6% during the 1st quarter. Paradigm Capital Management Inc. NY now owns 4,012,698 shares of the life sciences company's stock worth $37,800,000 after purchasing an additional 1,347,700 shares during the last quarter. Wellington Management Group LLP lifted its stake in Integra LifeSciences by 12.4% in the 2nd quarter. Wellington Management Group LLP now owns 1,461,104 shares of the life sciences company's stock valued at $26,241,000 after purchasing an additional 160,814 shares during the last quarter. Bank of America Corp DE grew its holdings in Integra LifeSciences by 71.4% during the first quarter. Bank of America Corp DE now owns 1,414,509 shares of the life sciences company's stock worth $13,325,000 after purchasing an additional 589,408 shares during the period. Glenmede Trust Co. NA grew its holdings in Integra LifeSciences by 27.4% during the first quarter. Glenmede Trust Co. NA now owns 984,686 shares of the life sciences company's stock worth $9,276,000 after purchasing an additional 211,774 shares during the period. Finally, Access Investment Management LLC grew its holdings in Integra LifeSciences by 72.0% during the first quarter. Access Investment Management LLC now owns 640,535 shares of the life sciences company's stock worth $6,034,000 after purchasing an additional 268,085 shares during the period. Institutional investors and hedge funds own 84.78% of the company's stock.

Integra LifeSciences News Summary

Here are the key news stories impacting Integra LifeSciences this week:

• Positive Sentiment: Adjusted earnings beat estimates: Integra reported third-quarter adjusted EPS of $0.59, above the $0.56 consensus and up from $0.54 a year earlier. GAAP EPS improved to $0.19 from a $0.07 loss, while operating cash flow reached $96 million. Integra LifeSciences Surpasses Q3 Earnings Estimates
• Positive Sentiment: Debt refinancing reduces near-term maturity risk: Integra completed a $2.1 billion refinancing that extends maturities and provides additional covenant capacity. Net debt declined to approximately $1.52 billion, and the leverage ratio fell to 3.8x. However, the company expects interest expense to increase toward the high end of its previously forecast 100-to-200-basis-point range. Integra LifeSciences Refinancing
• Neutral Sentiment: Revenue grew modestly: Third-quarter revenue increased 2.3% year over year to $411.2 million, broadly near expectations. Specialty Surgery revenue rose 3.9%, led by neurosurgery, while the company maintained its full-year 2026 revenue and adjusted EPS guidance of $1.634 billion–$1.654 billion and $2.30–$2.40, respectively. Integra Reports Third-Quarter Results
• Negative Sentiment: Weak outlook and operating disruptions weigh on shares: Integra forecast fourth-quarter revenue of $413 million–$433 million, implying a year-over-year decline of up to 5.2%. Cincinnati flood damage reduced quarterly revenue by about $7 million, while Tissue Reconstruction revenue fell 2.2% and adjusted gross margin declined to 61.1% from 62.9%. Integra Falls as Tissue Reconstruction Woes Add to Flooding Worries
• Negative Sentiment: Analyst sentiment deteriorated: JPMorgan lowered its price target from $17 to $14 and assigned an “underweight” rating. Truist also reduced its target from $19 to $15, reinforcing concerns about slower growth and execution. JPMorgan Cuts Integra Price Target
• Negative Sentiment: Legal overhang remains: Kirby McInerney LLP said it is continuing an investigation into potential securities-law violations and other alleged misconduct involving Integra and senior management, adding reputational and litigation risk. Integra Investor Investigation

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation NASDAQ: IART is a global medical technology company that develops and manufactures products used in neurosurgery, reconstructive surgery, orthopedics and wound care. Its portfolio includes medical devices, surgical instruments and regenerative tissue technologies designed to help healthcare professionals treat complex conditions and support patient recovery.

Integra's neurosurgical products include dural repair products, cerebrospinal fluid management systems, cranial stabilization devices and specialized surgical instruments.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.